ArticleCancer medicine2026
The Differences in Clinical Outcomes for Unresectable Huge (≥ 10 cm) Hepatocellular Carcinoma With Portal Vein Thrombosis Treated by Two Different Radiotherapy Techniques.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsTo explore a safe and effective treatment modality for unresectable huge (≥ 10 cm) hepatocellular carcinoma with portal vein thrombosis. And to provide more data on the synergistic antitumor effects of radiotherapy combined with immune checkpoint inhibitors and antiangiogenic therapy. MATERIALS AND
methodsThis study compared the clinical outcomes in 63 patients with unresectable huge hepatocellular carcinoma and portal vein thrombosis who were treated with either γ-ray body radiotherapy or linear accelerator radiotherapy (the RTγ and RTa groups, respectively), both combined with immune checkpoint inhibitors and antiangiogenic therapy.
resultsThe median progress-free survival (PFS) and median overall survival (OS) in the RTγ group were 12.1 and 14.3 months, respectively. And those in the RTa group were 6.6 and 8.1 months, respectively. The 1-, 2-, and 3-year PFS were 43.2%, 24.3%, 10.8% in the RTγ group and 11.5%, 3.8%, 0% in the RTa group, respectively. The OS at the same intervals were 56.7%, 40.5%, and 18.9% in the RTγ group, and those were 23.1%, 7.7%, and 0% in the RTa group, respectively. The percentage of normal liver volume (NLV) in whole liver volume (WLV) > 60% and negative viral infection are significant independent factors for superior PFS and OS. Severe radiation-induced liver disease was observed in 23.1% (n = 6) of patients in the RTa group, compared to none in the RTγ group.
conclusionsRTγ combined with immune checkpoint inhibitors and antiangiogenic therapy is an effective and safe treatment modality for unresectable huge hepatocellular carcinoma with portal vein thrombosis. An NLV/WLV ratio > 60% and negative viral infection independently predicted better PFS and OS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.